|
AltruGen intends to develop drugs for the poorly understood
oncology complication of Radiation Therapy-Induced Fibrosis
(RTIF). AltruGen possesses over 20 years of cancer research
and pathology experience and has partnerships with extensive
clinical experience in Radiation-Oncology.
With a well-established
team, AltruGen will immediately begin Phase II trials for its
prevention and treatment of RTIF. Other applications have also
been identified for this technology and AltruGen will actively
pursue opportunities to increase its IP and pipeline of oncology-related drugs. |
